Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.19
ALR's Cash-to-Debt is ranked lower than
84% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. ALR: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
ALR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.14 Max: 1.88
Current: 0.19
0.08
1.88
Equity-to-Asset 0.35
ALR's Equity-to-Asset is ranked lower than
77% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ALR: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
ALR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.15  Med: 0.38 Max: 0.77
Current: 0.35
0.15
0.77
Interest Coverage 0.24
ALR's Interest Coverage is ranked lower than
99% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.15 vs. ALR: 0.24 )
Ranked among companies with meaningful Interest Coverage only.
ALR' s Interest Coverage Range Over the Past 10 Years
Min: 0.24  Med: 0.64 Max: 1.37
Current: 0.24
0.24
1.37
Piotroski F-Score: 3
Altman Z-Score: 0.77
Beneish M-Score: -2.69
WACC vs ROIC
1.74%
1.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 1.88
ALR's Operating Margin % is ranked lower than
52% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ALR: 1.88 )
Ranked among companies with meaningful Operating Margin % only.
ALR' s Operating Margin % Range Over the Past 10 Years
Min: -44.13  Med: 3.85 Max: 7.6
Current: 1.88
-44.13
7.6
Net Margin % -1.64
ALR's Net Margin % is ranked lower than
51% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.05 vs. ALR: -1.64 )
Ranked among companies with meaningful Net Margin % only.
ALR' s Net Margin % Range Over the Past 10 Years
Min: -47.2  Med: -2.92 Max: 8.38
Current: -1.64
-47.2
8.38
ROE % -2.95
ALR's ROE % is ranked lower than
51% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. ALR: -2.95 )
Ranked among companies with meaningful ROE % only.
ALR' s ROE % Range Over the Past 10 Years
Min: -34.13  Med: -3.78 Max: 9.33
Current: -2.95
-34.13
9.33
ROA % -0.65
ALR's ROA % is ranked higher than
53% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. ALR: -0.65 )
Ranked among companies with meaningful ROA % only.
ALR' s ROA % Range Over the Past 10 Years
Min: -15.33  Med: -1.1 Max: 3.27
Current: -0.65
-15.33
3.27
ROC (Joel Greenblatt) % 0.94
ALR's ROC (Joel Greenblatt) % is ranked higher than
52% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. ALR: 0.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -169.25  Med: 10.95 Max: 22.61
Current: 0.94
-169.25
22.61
3-Year Revenue Growth Rate -1.00
ALR's 3-Year Revenue Growth Rate is ranked lower than
62% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. ALR: -1.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 8.2 Max: 36.1
Current: -1
-8.6
36.1
3-Year EBITDA Growth Rate -8.90
ALR's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. ALR: -8.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.3  Med: 7 Max: 102.9
Current: -8.9
-9.3
102.9
3-Year EPS without NRI Growth Rate -21.60
ALR's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. ALR: -21.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.6  Med: -9.3 Max: 76.1
Current: -21.6
-57.6
76.1
GuruFocus has detected 3 Warning Signs with Alere Inc $ALR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ALR Guru Trades in Q1 2016

Jeremy Grantham 736,344 sh (New)
George Soros 42,800 sh (New)
Mario Gabelli 494,105 sh (+109.87%)
Private Capital 933,725 sh (+0.34%)
Manning & Napier Advisors, Inc Sold Out
Steven Cohen Sold Out
Keeley Asset Management Corp 713,314 sh (-26.02%)
Jim Simons 506,724 sh (-42.31%)
Diamond Hill Capital 1,052,078 sh (-54.38%)
» More
Q2 2016

ALR Guru Trades in Q2 2016

Leucadia National 79,457 sh (New)
First Eagle Investment 766,566 sh (New)
Jeremy Grantham 1,520,100 sh (+106.44%)
Mario Gabelli 528,225 sh (+6.91%)
Diamond Hill Capital 1,074,665 sh (+2.15%)
George Soros Sold Out
Private Capital 849,998 sh (-8.97%)
Jim Simons 408,824 sh (-19.32%)
Keeley Asset Management Corp 520,100 sh (-27.09%)
» More
Q3 2016

ALR Guru Trades in Q3 2016

John Burbank 6,348 sh (New)
Steven Cohen 6,900 sh (New)
Diamond Hill Capital 2,313,104 sh (+115.24%)
First Eagle Investment 1,167,301 sh (+52.28%)
Jim Simons Sold Out
Leucadia National Sold Out
Private Capital 830,928 sh (-2.24%)
Keeley Asset Management Corp 463,995 sh (-10.79%)
Mario Gabelli 436,660 sh (-17.33%)
Jeremy Grantham 391,000 sh (-74.28%)
» More
Q4 2016

ALR Guru Trades in Q4 2016

Joel Greenblatt 123,245 sh (New)
George Soros 5,300 sh (New)
Leucadia National 40,000 sh (New)
Eric Mindich 1,000 sh (New)
Jim Simons 76,000 sh (New)
First Eagle Investment 1,663,161 sh (+42.48%)
Jeremy Grantham 476,484 sh (+21.86%)
Diamond Hill Capital 2,424,257 sh (+4.81%)
John Burbank Sold Out
Steven Cohen Sold Out
Private Capital 759,047 sh (-8.65%)
Mario Gabelli 380,545 sh (-12.85%)
Keeley Asset Management Corp 403,105 sh (-13.12%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB323.003.643 % Conv Perp Pfd Shs Series -B-

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:OTCPK:CZMWY, NAS:PRXL, NAS:PRAH, NAS:BRKR, NYSE:CRL, NAS:NEOG, NAS:EXAS, NAS:ICLR, NAS:AXDX, NYSE:BIO.B, NAS:MYGN, NAS:ABAX, NAS:ALOG, NAS:GHDX, NYSE:PKI, NAS:FMI, NAS:BEAT, OTCPK:BMXMF, NYSE:ARA, NAS:QDEL » details
Traded in other countries:IM5.Germany,
Alere Inc enables individuals to take charge of improving their health and quality of life at home. The Company operates in three segments; professional diagnostics, health information solutions and consumer diagnostics.

Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation incorporated on August 25,1992, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take control of their health at home, under the supervision of their healthcare providers, by connecting diagnostics in the hands of patients to their healthcare providers. The Company is a provider of point-of-care diagnostics and services; and has developed a commercial presence in infectious disease, toxicology, cardiology and diabetes. Its products and services help healthcare practitioners make earlier, more effective treatment decisions and improve outcomes for individuals living with chronic disease. Its portfolio also includes a broad array of health information solutions that increase access to critical health data, provide clinical decision support and facilitate more comprehensive performance reporting and analysis. The Company's operating segments are professional diagnostics, health information solutions and consumer diagnostics. Professional Diagnostics solutions allow patients and their healthcare providers to work together to manage patients' chronic conditions over the continuum of care, from the hospital to home. It is generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which defined as testing or monitoring performed at home under the supervision of a medical professional. Its products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. In professional diagnostics, Company focus on point-of-care, rapid diagnostic testing and the developing patient self-testing and patient self-management markets where it can directly and immediately improve patient health outcomes. Its products include point-of-care and laboratory tests within the following areas; Infectious Disease, Toxicology, Cardiology, Diabetes, Oncology, Women's Health and Connected Device Technologies. Its health information solutions are designed to provide physicians with actionable data that allows them to make more effective decisions in real time, deliver quality care, and put the individuals treat on a pathway to health. It offers a variety of software-based analytics, clinical decision-support tools, and accountable care programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcomes at both a patient and population le

Guru Investment Theses on Alere Inc

Diamond Hill Capital Comments on Alere Inc - Mar 17, 2015

Diagnostic systems provider Alere, Inc. (ALR) declined after installing a new CEO during the quarter, while weathering an unsolicited attempt by the previous CEO to take the company private. Subsequently, the company announced that it would sell its Health Management business in a first sign of the implementation of a new agenda focused on asset sales and debt paydown.

From Diamond Hill Capital (Trades, Portfolio)’s Select Fund Q4 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Alere Inc

Alere's Shareholders Approve Merger With Abbott Seventy-seven percent voted 'yes'
Last Friday, 77% of Alere Inc. (NYSE:ALR)'s shareholders approved a merger with Abbott Laboratories (NYSE:ABT). Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 17.48
ALR's Forward PE Ratio is ranked higher than
74% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.08 vs. ALR: 17.48 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 56.26
ALR's Price-to-Owner-Earnings is ranked lower than
82% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.26 vs. ALR: 56.26 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.14  Med: 22.02 Max: 2417.22
Current: 56.26
9.14
2417.22
PB Ratio 2.27
ALR's PB Ratio is ranked higher than
66% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.51 vs. ALR: 2.27 )
Ranked among companies with meaningful PB Ratio only.
ALR' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.73 Max: 3.21
Current: 2.27
0.42
3.21
PS Ratio 1.37
ALR's PS Ratio is ranked higher than
79% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. ALR: 1.37 )
Ranked among companies with meaningful PS Ratio only.
ALR' s PS Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.42 Max: 3.97
Current: 1.37
0.53
3.97
Price-to-Free-Cash-Flow 22.64
ALR's Price-to-Free-Cash-Flow is ranked higher than
57% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.89 vs. ALR: 22.64 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.02  Med: 19.51 Max: 112.72
Current: 22.64
7.02
112.72
Price-to-Operating-Cash-Flow 15.08
ALR's Price-to-Operating-Cash-Flow is ranked higher than
59% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.95 vs. ALR: 15.08 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.63  Med: 11.9 Max: 124.49
Current: 15.08
4.63
124.49
EV-to-EBIT 710.87
ALR's EV-to-EBIT is ranked lower than
100% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.75 vs. ALR: 710.87 )
Ranked among companies with meaningful EV-to-EBIT only.
ALR' s EV-to-EBIT Range Over the Past 10 Years
Min: -676  Med: 48.85 Max: 786.7
Current: 710.87
-676
786.7
EV-to-EBITDA 21.06
ALR's EV-to-EBITDA is ranked lower than
72% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.68 vs. ALR: 21.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.6  Med: 13.9 Max: 87.3
Current: 21.06
-173.6
87.3
Current Ratio 2.14
ALR's Current Ratio is ranked lower than
58% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.70 vs. ALR: 2.14 )
Ranked among companies with meaningful Current Ratio only.
ALR' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.78 Max: 3.42
Current: 2.14
0.7
3.42
Quick Ratio 1.65
ALR's Quick Ratio is ranked lower than
61% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ALR: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
ALR' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.35 Max: 2.89
Current: 1.65
0.46
2.89
Days Inventory 95.83
ALR's Days Inventory is ranked lower than
60% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 75.58 vs. ALR: 95.83 )
Ranked among companies with meaningful Days Inventory only.
ALR' s Days Inventory Range Over the Past 10 Years
Min: 80.21  Med: 92.61 Max: 104.46
Current: 95.83
80.21
104.46
Days Sales Outstanding 65.11
ALR's Days Sales Outstanding is ranked lower than
51% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. ALR: 65.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.28  Med: 67.28 Max: 79.93
Current: 65.11
60.28
79.93
Days Payable 58.14
ALR's Days Payable is ranked higher than
50% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.14 vs. ALR: 58.14 )
Ranked among companies with meaningful Days Payable only.
ALR' s Days Payable Range Over the Past 10 Years
Min: 45.36  Med: 52.02 Max: 59
Current: 58.14
45.36
59

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.50
ALR's 5-Year Yield-on-Cost % is ranked lower than
87% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. ALR: 0.50 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.5
3-Year Average Share Buyback Ratio -2.20
ALR's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ALR: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -60.8  Med: -3.4 Max: 19.3
Current: -2.2
-60.8
19.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.13
ALR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ALR: 1.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.17 Max: 6.47
Current: 1.13
0.45
6.47
Price-to-Median-PS-Value 0.96
ALR's Price-to-Median-PS-Value is ranked higher than
56% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. ALR: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.96 Max: 2.84
Current: 0.96
0.36
2.84
Earnings Yield (Greenblatt) % 0.10
ALR's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. ALR: 0.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 1.7 Max: 3.1
Current: 0.1
0.1
3.1

More Statistics

Revenue (TTM) (Mil) $2,395
EPS (TTM) $ -0.71
Beta-0.67
Short Percentage of Float2.68%
52-Week Range $31.47 - 53.95
Shares Outstanding (Mil)87.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,394 2,422 2,523
EPS ($) 2.44 2.27 2.46
EPS without NRI ($) 2.44 2.27 2.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.71%
Dividends per Share ($) 0.25 0.25
» More Articles for ALR

Headlines

Articles On GuruFocus.com
Abbott Laboratories Announces Quarterly Dividend Dec 09 2016 
Alere's Shareholders Approve Merger With Abbott Oct 23 2016 
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 
Keeley Small Cap Value Fund 1st Quarter Commentary Apr 26 2016 
The Transformation in Alere May 22 2015 
Diamond Hill Capital Comments on Alere Inc Mar 17 2015 
Corsair Capital's Analysis of Alere Mar 06 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
Mario Gabelli Comments on Alere Inc Nov 21 2014 

More From Other Websites
Alere delays annual filing for second year in a row Mar 01 2017
Alere's Bad News Tests the Limits of Patience Mar 01 2017
Early movers: ALR, MU, CRM, TIME, TRCO, INTC, ETSY & more Mar 01 2017
Diagnostic company Alere says to delay filing annual report Mar 01 2017
Wall Street's M&A Chatter From January 25 Jan 26 2017
European Commission Clears Abbott Acquisition of Alere Jan 25 2017
EU clears Abbott acquisition of Alere subject to divestments Jan 25 2017
Alere, Inc. breached its 50 day moving average in a Bearish Manner : ALR-US : January 24, 2017 Jan 24 2017
Lifshitz & Miller Law Firm Announces Investigation of Abeona Therapeutics Inc., Agile Therapeutics,... Jan 18 2017
Faruqi & Faruqi, LLP is Investigating Alere Inc. (ALR) on Behalf of its Shareholders Jan 17 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alere... Jan 11 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alere Inc.... Jan 10 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of... Jan 10 2017
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Alere Inc. and... Jan 09 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Jan 06 2017
Alere Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC... Jan 06 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alere Inc. and... Jan 06 2017
Alere Forensic Toxicology Division Gets ABFT Accreditation Jan 06 2017
Alere, Inc. breached its 50 day moving average in a Bullish Manner : ALR-US : January 6, 2017 Jan 06 2017
DEADLINE ALERT: Brower Piven Reminds Investors Of The January 13, 2017 Deadline In Class Action... Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)